Retina

European investigators describe how they address complications associated with silicone oil endotamponade in vitreoretinal surgery.

The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.

Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

The investigators retrospectively analysed treatment-naive eyes with DMO which received intravitreal treatment with either ranibizumab 0.5 mg or aflibercept 2 mg. All data were collected via Fight Retinal Blindness! registry.

The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.

The contest will take place at EURETINA 2022 as part of World Retina Day on Saturday 3 September 2022 from 8.30am to 9.30am CEST in Hall X2/Channel 7.

One systematic review and meta-analysis finds bariatric surgery associated with fewer cases of diabetic retinopathy overall and of sight-threatening progression.

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

Moving past the eyes and into the brain: It is vital to think beyond the eye in the presence of visual impairment and blindness.

CAM encourages corneal healing in patients with ocular surface disease.

In a study, investigators found that no characteristics of inflammatory bowel disease are related to ocular manifestations of the disease.

Dr Jayanth Sridhar shares a day in the life of an academic retina specialist.

Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.

Recent reports of retinal atrophy have raised concerns on potential long-term safety.

The findings of this study may have revealed the crucial role of gene fragments in retinal development and vision.

A novel computational platform identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

No effect when used with orthokeratology lenses for 2 years.

According to the Nanoscope Therapeutics, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.

At ASRS 2022, Dr Sally Ong presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicentre Study.” Here she shares the biggest takeaways.

The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.

Dr Justis P. Ehlers dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.

KALAHARI study update; novel surgical approaches for progressive retinal detachments; and a new risk is identified for CST fluctuations.

Metformin may provide AMD protection; DAVIO presents positive 12-month results; TOWER study reveals new imaging index for AMD.

Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.

Dr Dilsher Dhoot discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.

Dr Steven Yeh provides a brief overview of available therapies for noninfectious uveitis and uveitis macular oedema.